A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb5871 on Systemic Lupus Erythematosus Disease Activity
A study for patients with lupus using the study drug XmAb5871.
Sponsor: Xencor, Inc
Enrolling: Male and Female Patients
Study Length: 253 Days
Clinic Visits: 20
IRB Number: AAAQ2955
U.S. Govt. ID: NCT02725515
Contact: Anca Askanase MD MPH: 212-305-0856 / ada20@cumc.columbia.edu
Additional Study Information: The purpose of this clinical trial is to learn about the ability of an experimental treatment XmAb5871 to maintain lupus disease activity improvement achieved by a brief course of disease-suppressing intramuscular (IM) steroid therapy in lupus patients.
This study is closed
Investigator
Anca Askanase, MD, MPH
Do You Qualify?
Have you been diagnosed with lupus? Yes No
Would you agree to discontinue your current immunosuppressant SLE medications and receive a brief course of IM steroids? Yes No
Should you qualify for this study, would you agree to use medically acceptable methods of contraception? Yes No
Are you pregnant or breast feeding or planning to become pregnant while enrolled in the study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Anca Askanase MD MPH
ada20@cumc.columbia.edu
212-305-0856
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE